Procyon Biopharma Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: thebeach who wrote (338)	11/12/2002 6:24:21 PM
From: thebeach	Read Replies (1) of 356

International Medical Innovations Procyon has entered into a licensing agreement with IMI International Medical Innovations Inc. granting IMI the worldwide exclusive license to develop, market and distribute its colorectal cancer screening technology COLOPATH® in exchange for upfront and milestones payments as well as royalty on sales of any rectal mucus-based diagnostic test for colorectal cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next